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ABSTRACT 
 
 
Liver fibrosis results from chronic damage and excessive regeneration with redundant 
accumulation of extracellular matrix proteins, including collagen. Liver fibrosis may be 
caused by infectious, environmental, and autoimmune factors. Liver fibrosis is a precursor 
of cirrhosis and hepatocellular carcinoma. Current treatment options for liver fibrosis are 
primarily directed at inflammation with few options available to combat fibrogenesis. 
Pirfenidone (Esbriet®) is an anti-fibrotic agent for treatment of idiopathic pulmonary 
fibrosis, which downregulates the production of growth factors and procollagens I and II 
and inhibits fibroblast proliferation. We aimed to test anti-fibrotic potential of pirfenidone 
in liver using mouse model of sub-chronic cytotoxic fibrosis induced by carbon 
tetrachloride (CCl4). Additionally, considering its anti-fibrotic properties, pirfenidone was 
expected to suppress chemically-induced carcinogenesis.  
Several studies were conducted to evaluate effects of pirfenidone in liver. First, a 4-week 
dose-finding study was performed, male B6C3F1/J mice were treated with CCl4 (0.2 ml/kg 
intraperitoneal injections twice a week) while on diet with varying doses of pirfenidone (0 
mg/kg, 100 mg/kg, 300 mg/kg, 600 mg/kg). Second, a 14-week subchronic study was 
conducted, where male B6C3F1/J mice were treated with CCl4 twice a week while on 300 
mg/kg pirfenidone dose diet. Third, a 24-week anti-cancer study was performed, in which 
112 male B6C3F1/J mice were exposed to single injection of either N-nitrosodiethylamine 
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(DEN) or phosphate-buffered saline, followed with 14-week treatment by either olive oil 
or CCl4 in combination with either pirfenidone (300 mg/kg) or control diet. 
Pirfenidone treatment decreased liver fibrosis in both studies. In dose-finding study, 
pirfenidone had a significant anti-fibrotic and anti-inflammatory effect by significantly 
blunting collagen deposition in liver, serum transaminase levels, and preventing 
ballooning degeneration of hepatocytes at 300 and 600 mg/kg doses. In sub-chronic study, 
pirfenidone treatment also resulted in a significant reduction in collagen deposition in 
liver; however, it had little effect on inflammatory markers and liver injury. In anti-cancer 
study, pirfenidone did not affect incidence, size, or multiplicity of tumors. 
Pirfenidone showed anti-fibrogenesis effects in sub-acute and sub-chronic cytotoxic liver 
fibrosis model; anti-inflammatory effects were observed only in sub-acute study. 
Pirfenidone has no effect on development of liver tumors in anti-cancer study. 
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NOMENCLATURE 
CCl4 – carbon tetrachloride 
DEN - N-nitrosodiethylamine 
OO – olive oil 
PBS – phosphate-buffered saline 
PFD - pirfenidone 
CD – control diet 
FDA – U.S. Food and Drug Administration 
ECM – extracellular matrix 
HSC – hepatic stellate cell 
PDGF - platelet-derived growth factor 
SREBP-1c - sterol regulatory element-binding protein 1c 
PPAR - peroxisome proliferator-activated receptor alpha 
ROS – reactive oxygen species 
HCC – hepatocellular carcinoma 
IPF – idiopathic pulmonary fibrosis 
TGF- - transforming growth factor beta 1 
TNF- - tumor necrosis factor alpha 
ET-1 - endothelin 1 
IFN- – interferon gamma 
SDF-1 - stromal cell-derived factor 1 
FGF – fibroblast growth factor 
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COL1A1 – collagen type I, alpha 1 chain 
IL - interleukin 
CYP – cytochrome P 
MCP-1 - monocyte chemoattractant protein-1 
PFD_DS – pirfenidone dose-finding study 
PFD_AS – pirfenidone sub-chronic anti-fibrotic study 
PFD_MS – pirfenidone anti-cancer study 
H&E – hematoxylin and eosin 
ALT – alanine aminotransferase 
AST – aspartate aminotransferase 
CD68 – cluster of differentiation 68 
KIM-1 – kidney injury molecule-1 
RNA - ribonucleic acid 
RT-qPCR – quantitative reverse transcription polymerase chain reaction 
IACUC - Institutional Animal Care and Use Committee 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Liver fibrosis: Etiology, pathogenesis, complications, management 
Liver fibrosis is a pathologic condition, which develops as a result of repeated, chronic 
damage, and is characterized by excessive regeneration of parenchyma after progressive 
destruction, which leads to redundant accumulation of extracellular matrix proteins, 
including collagen.  
Etiologic factors which lead to the development of liver fibrosis are numerous and include 
various infections (viral – e.g., hepatitis B and hepatitis C viruses; bacterial – e.g., 
brucellosis; parasitic – e.g., echinococcosis), heavy alcohol consumption with resulting 
alcoholic liver disease, non-alcoholic fatty liver disease and nonalcoholic steatohepatitis, 
autoimmune liver diseases (autoimmune hepatitis, primary biliary cholangitis, primary 
sclerosing cholangitis), certain storage diseases and inborn errors of metabolism (alpha-1 
antitrypsin deficiency, Wilson’s disease, fructosemia, galactosemia, glycogen storage 
diseases, hemochromatosis, Gaucher disease, Zellweger syndrome, tyrosinemia), 
congenital conditions (e.g., congenital hepatic fibrosis) and trauma, as well as multiple 
medications and toxins [1, 2].  
The onset of liver fibrosis is usually asymptomatic. Pathogenesis of hepatic fibrosis 
constitutes a wound-healing response of the liver to repeated injury, and involves 
regeneration of parenchymal cells with their replacement of apoptotic and necrotic cells. 
If hepatic injury persists for a long time, liver regeneration eventually fails, and 
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hepatocytes are replaced with abundant extracellular matrix (ECM), including collagen. 
The distribution of ECM is dependent on the type of liver injury, with chronic viral 
infections and chronic cholestatic conditions resulting in initial deposition of ECM around 
portal tracts, whereas alcohol-induced liver disease results in deposition of fibrous tissue 
in pericentral and perisinusoidal regions. There are major differences in ECM composition 
and quantity (6 times more ECM than normal, including collagens I, III, IV, fibronectin, 
undulin, elastin, laminin, hualuronan, proteoglycans) in advanced stages of liver fibrosis, 
compared to normal liver [1, 3].  
Hepatic stellate cells (HSCs) are located in the space of Disse, and are main contributors 
to ECM deposition in the case of liver injury. In case of chronic liver injury, HSCs activate 
or transdifferentiate into myofibroblast-like cells and obtain contractile, proinflammatory 
and fibrogenic properties. After activation, HSCs migrate and accumulate at the sites of 
tissue regeneration and secrete massive amounts of ECM, while also regulating ECM 
degradation. PDGF, which is primarily produced by Kupffer cells, is the predominant 
mitogen for activated HSCs [1, 2]. Synthesis of collagen in HSCs is regulated at both 
transcriptional and posttranscriptional levels. Quiescent HSCs express markers 
characteristic of adipocytes (SREBP-1c, PPARγ, and leptin), whereas activated HSCs 
express markers of myogenesis (c-myb, α smooth muscle actin, and myocyte enhancer 
factor–2). Myofibroblasts derived from small portal vessels also possess potential for 
fibrogenesis [1, 2]. 
Relative importance of different cell types in hepatic fibrogenesis is dependent on the 
origin of liver injury, and complex interactions between various cell types take place. 
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Injured hepatocytes release ROS and fibrogenic mediators and stimulate the recruitment 
of white blood cells by inflammatory cells [1]. 
In the majority of patients, without proper prophylaxis (e. g., avoidance of harmful 
substances and prompt treatment of chronic viral hepatitis infections) liver fibrosis 
eventually (usually after 15-20 years) progresses to liver cirrhosis and hepatocellular 
carcinoma, both of which are severe diseases that constitute a significant segment of 
morbidity and mortality causes worldwide [1, 3]. 
Liver cirrhosis is a diffuse pathologic process in liver, which is characterized as an 
advanced fibrosis with conversion of regular hepatic architecture to structurally aberrant 
cirrhotic nodules. Progression from hepatic fibrosis to cirrhosis may occur over different 
amount of years, depending on scale and duration of liver injury [2, 3].  
In United States, cirrhosis is the 9th leading cause of death, and holds responsibility for 
1.2% of all deaths, with the majority of patients’ deaths occurring in their fifth or sixth 
decades of life. Worldwide, cirrhosis is the 14th most common mortality cause, although 
in Europe, it is the 4th most common cause of death [2, 3]. 
Some patients with cirrhosis are asymptomatic and may have relatively normal life 
expectancy, while other develop a range of symptoms that constitute end-stage liver 
disease and hold a limited capability of survival. Common signs and symptoms of cirrhosis 
are derived from decrease in hepatic systemic function (coagulopathy), reduction of 
hepatic detoxification capacities (hepatic encephalopathy), or chronic increase in venous 
pressure in portal vein (portal hypertension) [2, 3]. 
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Treatment of cirrhosis is primarily aimed at pharmacologic and procedural management 
of complications, and bears purely symptomatic relief. Liver transplantation has been 
evolved as an important strategy in management of decompensated cirrhosis, with quality 
of life after liver transplant being reported as good or excellent in most cases [2, 3]. 
Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver, which, in the 
majority of cases, occurs in patients with preexisting chronic liver disease and cirrhosis. 
HCC progress with intrahepatic spread, local expansion, and by metastatic dissemination.  
Over the past 20 years, incidence of HCC has grown more than twice, from 2.6 to 5.2 per 
100,000 population. The incidence of hepatocellular carcinoma is highest in Asia and 
Africa, and derives from high prevalence of chronic hepatitis B and C infections, presence 
of which is a strong predisposition for manifestation of chronic liver disease, which 
subsequently leads to development of HCC. Hepatocellular carcinoma is currently a third 
leading cause of cancer-related deaths in the world, and is the fastest growing cause of 
cancer mortality overall – over the last decade, mortality from HCC increased from 2.8 to 
4.7 per 100,000 population [4, 5].  
In the past, HCC in most cases presented at advanced stage, with signs and symptoms 
corresponding to decompensated liver disease, weight loss, and right upper-quadrant pain. 
At the present time, HCC is primarily recognized at much earlier stage as a consequence 
of routine screening of individuals with established diagnosis of cirrhosis, utilizing cross-
sectional imaging studies and serum alpha-fetoprotein (AFP) measurements [4]. 
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Treatment options for liver fibrosis are scarce and, besides removal of the causative agent 
as a most effective intervention, primarily consist of suppression of chronic inflammation, 
which is a major mechanism of the liver fibrosis. Use of anti-inflammatory drugs has been 
suggested, and corticosteroids are indicated for the treatment of patients with autoimmune 
hepatitis and acute alcoholic hepatitis. Other experimental treatment strategies include 
antioxidants (such as vitamin E, silymarin, phosphatidylcholine, and S-adenosyl-L-
methionine), inhibitors of signal transduction pathways involved in liver fibrogenesis 
(pentoxifylline, amiloride, S-farnesylthiosalicylic acid), renin-angiotensin inhibitors, 
herbal compounds (Sho-saiko-to, glycyrrhizin, Salvia miltiorrhiza), and infusion of 
mesenchymal stem cells [1, 6].  
There is a range of non-organ-specific agents that are proposed to suppress fibrosis 
development by targeting various mechanisms of fibrosis development, such as TGF-β 
expression and activation (e.g., pirfenidone), TGF-β signaling pathways (e.g., imatinib, 
dasatinib), inhibition of fibrocyte homing (e.g., nintedanib, sorafenib), transcription 
factors (e.g., macrolide antibiotics, rosiglitazone) and other mechanisms (tocilizumab, 
bosentan, D-penicillamine) [6]. 
Idiopathic pulmonary fibrosis: Etiology, pathogenesis, management 
Idiopathic pulmonary fibrosis is a severe and progressive fibrotic interstitial disease of the 
lung with an ultimate outcome in form of respiratory failure and death. Median age of 
establishment of diagnosis is 66 years, and the incidence is increasing with advancement 
of age.  
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Currently, no single etiologic agent is established as a common inducement factor in 
development of IPF. It is currently believed that idiopathic pulmonary fibrosis is an 
epithelial-fibroblastic disease, in which unestablished environmental or endogenous 
stimuli disrupt the homeostasis of alveolar epithelial cells, resulting in widespread 
epithelial cell activation and abnormal epithelial cell repair [7].  
Exposure to an induction agent (e. g., smoke, environmental dust, environmental 
pollutants, viral infections, chronic aspiration, and gastroesophageal reflux disease) in a 
susceptible person may lead to alveolar epithelial damage, which is followed by aberrant 
activation of epithelial cells of the alveoli and subsequent migration, proliferation, and 
activation of mesenchymal cells, which leads to establishment of fibroblastic and 
myofibroblastic foci. The result of the process described above is excessive accumulation 
of ECM together with irreversible destruction of lung parenchyma [7].  
Upon activation, alveolar epithelial cells release several fibrogenic cytokines and growth 
factors, including tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-
β), platelet-derived growth factor, insulin-like growth factor-1, and endothelin-1 (ET-1), 
all of which are taking part in migration and proliferation of fibroblasts and following 
transformation of fibroblasts into myofibroblasts (both of which are key cells in 
fibrogenesis and secretion of ECM proteins). TGF-β showed anti-apoptotic phenotype-
promoting properties in fibroblasts. In contrast to normal apoptosis processes that take 
place in normal wound healing, failure of apoptosis in the event of IPF leads to 
myofibroblasts accumulation, excessive ECM protein production and pathologic scar 
formation [7].  
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There is a number of grave complications that may occur in patients with idiopathic 
pulmonary fibrosis, including pulmonary hypertension, respiratory infections, acute 
coronary syndrome, thromboembolic diseases, and lung cancer.  
Currently, there are only a few pharmacotherapeutic options for idiopathic pulmonary 
fibrosis, which can suppress the progression of the disease and improve quality of life for 
affected patients: nintedanib, which is an intracellular inhibitor that targets multiple 
tyrosine kinases, including CEGF, FGF, and PDGF receptors [8-10], and pirfenidone, 
which is a non-peptide broad-spectrum anti-fibrotic drug that decreases TGF-1, TNF-, 
PDGF and COL1A1 expression [7, 11, 12]. In addition, lung transplantation showed to 
achieve survival benefit over medical management [7]. 
Pirfenidone: Overview of anti-fibrotic properties and metabolism 
Pirfenidone (5 methyl-1-phenyl-2-(1H)-pyridone; Esbriet®) is an orally bioavailable, 
synthetic, pyridone compound, which is classified as an immunosuppressant. Pirfenidone 
is currently the only compound, beside nintedanib, that approved by FDA for the treatment 
of idiopathic pulmonary fibrosis (IPF) [6]. Existing data from in vitro studies and animal 
models of pulmonary fibrosis suggest that pirfenidone has antifibrotic, anti-inflammatory 
and antioxidant properties [11, 12]. 
Pirfenidone is thought to inhibit progression of fibrosis by affecting tissue levels of various 
cytokines, growth factors and chemokines. In animal models of pulmonary fibrosis, 
pirfenidone reduced TGF-β1 production in lungs [11]; in vitro, pirfenidone inhibited TGF-
β1-induced differentiation of human lung fibroblasts into myofibroblasts, preventing 
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excessive collagen synthesis and production of extracellular matrix proteins. In primary 
alveolar epithelial type II cells and primary lung myofibroblasts isolated from lung 
parenchyma of patients with IPF, pirfenidone exhibited dose-dependent prevention of pro-
proliferative effect of TGF-β1 [11-13]. Pirfenidone is thought to inhibit production of 
TGF-β1 by preventing reduction of antifibrotic cytokine IFN- through suppression of IL-
12p40 [6, 11, 12, 14] . Pirfenidone also exhibited suppression of fibroblast proliferation 
in vitro and reduced elevation of pulmonary levels of IL-18 (lung basic-fibroblast growth 
factor) and SDF-1 (stroma cell derived factor) in mouse model of pulmonary fibrosis 
[11].  
Anti-inflammatory properties exhibited by pirfenidone were attributed to its regulation of 
pulmonary inflammatory cytokines and inflammatory cells. Pirfenidone inhibited the 
release of proinflammatory cytokines such as IL-1β, IL-6, TNF-α, and PDGF (platelet-
derived growth factor) in animal models of pulmonary fibrosis [12]. Pirfenidone was noted 
to suppress IL-1β and TNF-α in alveolar macrophages obtained from bronchoalveolar 
lavage of patients with IPF [11, 12, 15]. Pirfenidone increased production of IL-10 (anti-
inflammatory cytokine) in a murine model of endotoxic shock; in addition, pirfenidone 
suppressed production of monocyte chemoattractant protein MCP-1 and decreased 
accumulation of various inflammatory cells, such as lymphocytes, macrophages and 
neutrophils in hamsters [12, 15]. In pulmonary fibrosis, activation of alveolar 
macrophages and phagocytosis of neutrophils results in release of ROS, which decreases 
function of alveolar-capillary beds through lipid peroxidation, resulting in cellular damage 
[12]. Malonaldehyde, end-product of lipid peroxidation, has been shown to stimulate 
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collagen synthesis. Pirfenidone scavenged ROS and suppressed lipid peroxidation and 
malonaldehyde activity in vitro and in animal models of pulmonary fibrosis [12, 15].  
Pirfenidone binds mainly to serum albumin in humans, and has an overall mean binding 
of 50-58% [12]. Pirfenidone was not widely distributed to tissues, with results of a pooled 
population pharmacokinetic analysis showing an approximate oral steady-state volume of 
distribution of ~70 L [12]. Pirfenidone is predominantly metabolized by cytochrome P450 
pathway. Approximately 70-80% of the compound being metabolized by CYP1A2; 
CYP2C9, CYP2C19, CYP2D6 and CYP2E1 also take part in metabolism of pirfenidone, 
albeit to a lesser extent [12]. Mean terminal elimination half-life of pirfenidone after the 
administration of a single dose of 801 mg in healthy older adults was approximately 2.4 h 
with food and 2.9 h without food; mean apparent oral clearance of pirfenidone was 13.8 
L/h with food and 11.8 L/h without food [12]. Within 24 h of oral administration, 
approximately 80 % of the pirfenidone dose was excreted in urine. 95% of pirfenidone 
was excreted as 5-carboxy-pirfenidone (primary metabolite of pirfenidone), with 1% of 
pirfenidone excreted unchanged and 0.1% excreted as other metabolites [12]. 
Pirfenidone is expected to suppress development of liver fibrosis and subsequent liver 
carcinogenesis by targeting same mechanisms of fibrosis as in IPF, and therefore it 
constitutes an interesting compound that could be used in appropriate experimental liver 
fibrosis and carcinogenesis model. 
 
 
 10 
 
 
Animal models of liver fibrosis and inflammation-associated HCC 
Due to genetic and physiologic similarities among rodents and humans, superior breeding 
capacity and short lifespan, rodents are often used as a study subjects in preclinical 
research. Experimental animal models constitute an irreplaceable source for clarification 
of molecular mechanisms of liver fibrosis and development of effective anti-fibrotic 
therapy strategies.  
Current animal models for research of liver fibrosis [16] include: 
 chemically induced fibrosis using hepatotoxic agents (carbon tetrachloride, 
thioacetamide, dimethylnitrosamine) 
 cholestatic fibrosis (bile duct ligation) 
 immunologically mediated fibrosis (concanavalin A, Schistosoma 
mansoni infection) 
In addition, targeted gene knockouts in mice are evolving as a powerful resource to address 
the development of mono- and polygenic pathologic conditions by focusing on stable or 
inducible gene disruption specifically in liver. Considerable amount of data on candidate 
genes for liver fibrogenesis is currently available resulting from targeted disruption of 
certain genes, such as IL-6, gp130, gp130/STAT3, SOCS3, SOCS1, Stat5, Bc1-xL, IL-10, 
fibroblast growth factor receptor 4, 53, adiponectin, TNF-, CHOP, CD14, leptin, and 
others [16]. Numerous rodent models have been used to define pathogenesis of 
hepatocellular carcinoma and have provided a significant contribution to the existing 
knowledge on HCC.  
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Current animal models for hepatocellular carcinoma research [17] include:  
 chemically induced models that are similar to chemically induced liver fibrosis 
models (administration of DEN, CCl4, aflatoxin, thiocetamide, peroxisome 
proliferators and other) 
 xenograft models (ectopic implantation, orthotopic implantation, hollow fiber 
model) 
 genetically modified models (utilizing viral genes, oncogenes and growth factors) 
DEN and CCl4-induced mouse model of fibrosis and inflammation-associated 
hepatocellular carcinoma [18] was developed by joint efforts of the researchers at 
University of North Carolina in Chapel Hill, North Carolina, and National Center of 
Toxicological Research in Jefferson, Arkansas. The disease model is achieved by initial 
intraperitoneal administration of N-nitrosodiethylamine (DEN) at 8 weeks of age, 
followed by repeated intraperitoneal administration of carbon tetrachloride (CCl4) over 14 
weeks. A significant potentiation of tumor incidence in liver is observed upon 
administration of described compounds, resulting in 100% of mice developing liver 
tumors at 5 months of age [18].  
The described model is a reproducible and effective animal study approach that is 
relatively simple to develop and maintain, and therefore it may be utilized to test anti-
fibrotic and anti-cancer efficacy of various compounds in liver, including pirfenidone. 
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CHAPTER II 
SPECIFIC AIMS 
Liver fibrosis and its complications in form of liver cirrhosis and hepatocellular carcinoma 
comprise significant portion of morbidity and mortality in human population, and the best 
prevention and treatment options are to avoid exposure to a causative agent and in its 
removal, respectively; however, those strategies are not always achievable [1]. 
Although many different experimental preventative and therapeutic approaches have been 
proposed to target progression of liver fibrosis and consequential carcinogenesis, none to 
this date were found to bear a desirable effect in form of reduction in intensity of liver 
fibrosis and decrease in incidence of tumorigenesis in livers of experimental animals. 
Therefore, this project is expected to bring innovation to the field of experimental and 
clinical hepatology by testing the antifibrotic and anticancer effects of the compound, 
which has been established as one of the primary treatment options of pulmonary fibrosis 
[6, 7, 12, 15], but never have been properly tested on hepatic fibrogenesis. 
This project is expected to bear a significance in development of new approaches for 
pharmacologic treatment of liver fibrosis and advanced stage, cirrhosis. Additionally, this 
project is directed towards targeting hepatic fibrogenesis as a stage of liver cancer 
development, so there is an expectation of decrease in incidence and multiplicity of liver 
tumors in experimental animals. Therefore, there is a possibility that acquired results 
would influence future decisions regarding applications of pirfenidone in human 
medicine.  
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Two separate specific aims were established in project to pursue stated goals. 
Specific Aim 1: To test the efficacy of pirfenidone, antifibrotic agent, in reduction of liver 
fibrosis in mice. 
Rationale: Pirfenidone has proven its efficacy in reducing pulmonary fibrosis through 
downregulation of the production of growth factors and procollagens I and II. As the 
mechanisms of fibrosis development are same throughout the organs, pirfenidone is 
anticipated to affect liver fibrosis as well.  
Hypothesis: We hypothesize that pirfenidone would reduce intensity of liver fibrosis in 
mice. 
Approach: To test this hypothesis, we conducted two studies to assess the efficacy of 
pirfenidone against liver fibrosis. First, we conducted a 4-week study (PFD_DS), in which 
fibrogenic agent CCl4 (0.2 ml/kg twice a week) and orally administered pirfenidone in 
three different doses (100 mg/kg, 300 mg/kg, and 600 mg/kg) were utilized in male mice. 
Second, we conducted a 14-week study (PFD_AS), in which fibrogenic agent CCl4 (0.2 
ml/kg twice a week) was used along with minimal effective oral dose of pirfenidone (300 
mg/kg), which was derived from 4-week study. 
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Specific Aim 2: To test the efficacy of pirfenidone, antifibrotic agent, in preventing 
carcinogenesis in liver. 
Rationale: Liver fibrosis is considered a precursor for the development of liver cancer, 
specifically hepatocellular carcinoma, in humans. Due to its antifibrotic activity, 
pirfenidone is expected to suppress fibrogenesis and, subsequently, negatively affect 
carcinogenesis. 
Hypothesis: We hypothesize that pirfenidone would reduce incidence, size and 
multiplicity of liver tumors in mice.  
Approach: To test this hypothesis, we conducted a 24-week initiation-promotion cancer 
study (PFD_MS), which tests the efficacy of pirfenidone in suppressing development of 
chemically induced liver tumors. In this study, single intraperitoneal injection of initiation 
agent DEN and consequent 14-week intraperitoneal administration of promotion agent 
CCl4 was utilized along with 14-week dietary application of pirfenidone in minimal 
effective antifibrotic dose (300 mg/kg), which was established in 4-week study from 
Specific Aim 1. 
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CHAPTER III 
MATERIALS AND METHODS 
Chemicals and diets 
DEN (N-nitrosodiethylamine) was obtained from Sigma-Aldrich (St. Louis, MO; CAS 
55-18-5). CCl4 (carbon tetrachloride) was obtained from Sigma-Aldrich (St. Louis, MO; 
CAS 56-23-5). Olive oil was obtained from Sigma-Aldrich (St. Louis, MO; CAS 8001-
25-0). Pirfenidone (5 methyl-1-phenyl-2-(1H)-pyridone) was obtained from Shionogi & 
Co., LTD (Osaka, Japan; CAS 53179-13-8). Control and pirfenidone-containing grain-
based rodent diets were manufactured by Custom Animal Diets, LLC (Easton, PA). BrdU 
(5-Bromo-2′-deoxyuridine) was obtained from Sigma-Aldrich (St. Louis, MO; CAS 59-
14-3). Nembutal was obtained from Oak Pharmaceutical (Lake Forest, IL). 
Experimental designs, dosing, and tissue collection 
This project consists of three arms, represented in Figure 1: pirfenidone antifibrotic dose-
finding study (PFD_DS), pirfenidone antifibrotic sub-chronic study (PFD_AS), and 
pirfenidone anti-cancer study (PFD_MS). PFD_DS targets the effects of different doses 
of pirfenidone on the reduction of liver fibrosis intensity in mice treated by CCl4. PFD_AS 
is an antifibrotic subchronic study that assesses the efficacy of 300 mg/kg dose of 
pirfenidone, established from PFD_DS, in the event of 14-week CCl4 administration. 
PFD_MS is an initiation-promotion liver cancer study that utilizes DEN and CCl4-induced 
mouse model of fibrosis and inflammation-associated hepatocellular carcinoma to test the 
efficacy of pirfenidone in reducing incidence, multiplicity and size of liver tumors. 
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Experimental design of pirfenidone antifibrotic dose-finding study (PFD_DS) 
7-week old male B6C3F1/J mice (n=40; The Jackson Laboratory, Bar Harbor, ME) arrived 
7 days before the start of experiment and were housed in regular cages in a temperature-
controlled (24°C) room, with a 12/12-hr light/dark cycle, and have been granted access to 
purified water and regular rodent diet ad libitum.  
After an acclimation period (7 days), the mice were randomly divided into four groups of 
10 mice. Beginning at 8 weeks of age, mice from the 1st group started receiving control 
grain-based rodent diet ad libitum. Mice from 2nd, 3rd and 4th groups started receiving 
custom grain-based rodent diet that contained pirfenidone in concentrations of 0.075% 
(equivalent to daily oral dose of 100 mg/kg), 0.225% (equivalent to daily oral dose of 300 
mg/kg), and 0.45% (equivalent to daily oral dose of 600 mg/kg), respectively. During first 
2 weeks of the study, all groups have received their respective diet in powder form due to 
technical delays with custom pellet diet shipping. Starting from 3rd week, half of mice in 
each group continued to receive their respective diet in powder form, while other half of 
animals started to receive pirfenidone diet in pellet form. Mice from each group were 
injected intraperitoneally with CCl4 (0.2 ml/kg, diluted in olive oil) twice a week for 4 
weeks. Body weight of the animals was assessed twice a week before the injections, and 
the dosage of CCl4 was adjusted accordingly to changes in body weight of the animals. 
During the treatment period, 2 mice from 600 mg/kg group died as a result of possible 
internal perforation injury, and Unanticipated or Adverse Event Form was submitted to 
IACUC via iRIS portal. 
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On the day following last, 8th injection, all animals were euthanized using Nembutal (100 
mg/kg intraperitoneal injection) and necropsies were performed. During each necropsy, 
body weight of animal was recorded, and blood, liver, kidneys, lungs and spleen were 
collected and weighted. One slice of left liver lobe, one slice of median liver lobe and one 
slice of kidney from each animal were put inside a plastic cassette and were fixed in 10% 
neutral buffered formalin for 48 hours. The remaining tissues were immediately frozen in 
liquid nitrogen and subsequently stored at -80°C for further analysis. All animals were 
treated humanely and major attention had been paid to alleviation of potential suffering. 
The experiment was approved by the Institutional Animal Care and Use Committee at 
Texas A&M University. The experimental design is described in Figure 2. 
 
 
 
 
 
 
 
 
Figure 2. Study design for dose-finding study (PFD_DS) 
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Experimental design of pirfenidone antifibrotic sub-chronic study (PFD_AS) 
7-week old male B6C3F1/J mice (n=20; The Jackson Laboratory, Bar Harbor, ME) arrived 
7 days before the start of experiment and were housed in regular cages in a temperature-
controlled (24°C) room, with a 12/12-hr light/dark cycle, and have been granted access to 
purified water and regular rodent diet ad libitum.  
After an acclimation period (7 days), the mice were randomly divided into four groups of 
5 mice. Beginning at 8 weeks of age, mice from the 1st and 3rd group started receiving 
control grain-based rodent diet ad libitum. Mice from 2nd and 4th groups started receiving 
custom grain-based rodent diet that contained pirfenidone in concentration of 0.225% 
(equivalent to daily oral dose of 300 mg/kg). Mice from 1st and 2nd groups were injected 
intraperitoneally by olive oil twice a week for 14 weeks, and mice from 3rd and 4th groups 
were injected intraperitoneally with CCl4 (0.2 ml/kg, diluted in olive oil) twice a week for 
14 weeks. Body weight of the animals was assessed twice a week before the injections, 
and the dosage of olive oil and CCl4 was adjusted accordingly to changes in body weight 
of the animals. During the treatment period, 1 mouse died as a result of possible internal 
perforation injury.  
On the day following last, 28th injection, all animals were euthanized using Nembutal (100 
mg/kg intraperitoneal injection) and necropsies were performed. During each necropsy, 
body weight of animal was recorded, and blood, liver, kidneys, lungs and spleen were 
collected and weighted. One slice of left liver lobe, one slice of median liver lobe and one 
slice of kidney from each animal were put inside a plastic cassette and were fixed in 10% 
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neutral buffered formalin for 48 hours. The remaining tissues were immediately frozen in 
liquid nitrogen and subsequently stored at -80°C for further analysis. All animals were 
treated humanely and major attention had been paid to alleviation of potential suffering. 
The experiment was approved by the Institutional Animal Care and Use Committee at 
Texas A&M University. The experimental design for this study is described in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Study design for sub-chronic study (PFD_AS) 
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Experimental design of pirfenidone anti-cancer study (PFD_MS) 
1-week old male B6C3F1/J mice (n=112; The Jackson Laboratory, Bar Harbor, ME) 
arrived 7 days before the start of experiment together with AXEAST: AX27 and 
AXEAST: AX28 female mice acting as foster mothers, with a maximum of 5 pups per 1 
foster mother (n=23; The Jackson Laboratory, Bar Harbor, ME). All mice were housed in 
regular cages in a temperature-controlled (24°C) room, with a 12/12-hr light/dark cycle, 
were granted access to purified water and regular rodent diet ad libitum, and were left 
intact for an acclimation period, which lasted 7 days. On 14th day after birth, the pups were 
randomly divided into two groups – 1st group of pups (n=97) receiving DEN (1 mg/kg, 
dissolved in phosphate-buffered saline, single intraperitoneal injection) and 2nd group of 
pups (n=15) receiving sterile phosphate-buffered saline (1 mg/kg, single intraperitoneal 
injection). At 10 weeks of age, all mice were split into four groups for the purpose of 
receiving appropriate diets (ad libitum) and corresponding chemical injections (twice 
weekly). Mice from the 1st group began receiving control diet. Mice from the 2nd, 3rd and 
4th groups began receiving diet containing 0.225% pirfenidone, equivalent to daily oral 
dose of 300 mg/kg. Starting from 10 weeks of age, mice from groups 1 and 2 were injected 
intraperitoneally with CCl4 (0.2 ml/kg, diluted in olive oil) and mice from groups 3 and 4 
were injected intraperitoneally by olive oil alone twice a week for 14 weeks. Body weight 
of the animals was assessed twice a week before the injections, and the dosage of CCl4 
and olive oil was adjusted accordingly. During the treatment period, 1 mouse from 
DEN+CCl4/CD group died as a result of possible internal perforation injury, and 
Unanticipated or Adverse Event Form was submitted to IACUC via iRIS portal. On the 
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day following last, 28th injection, all animals were euthanized using Nembutal (100 mg/kg 
intraperitoneal injection) and necropsies were performed. During each necropsy, body 
weight of animal was recorded, and blood, liver, kidneys, lungs and spleen were collected 
and weighted. Macroscopic evaluation and quantification of visible liver tissue tumors 
was performed. One slice of left liver lobe, one slice of median liver lobe, one slice of 
kidney, and a segment of duodenum from each animal were put inside a plastic cassette 
and were fixed in 10% neutral buffered formalin for 48 hours. The remaining tissues were 
immediately frozen in liquid nitrogen and stored at -80°C for further analysis. All animals 
were treated humanely and major attention had been paid to alleviation of potential 
suffering. The experiment was approved by the Institutional Animal Care and Use 
Committee. Experimental design of this study is shown in Figure 4. 
 
 Figure 4. Study design for anti-cancer study (PFD_MS) 
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Histopathological evaluation of liver tissue 
Tissues were embedded in paraffin, sectioned at 5 µm, and hematoxylin and eosin (H&E) 
and Sirius Red staining techniques of liver tissue were performed according to standard 
protocols. 
For H&E staining, samples were evaluated in a blind manner by a certified veterinary 
pathologist, and total histopathological score was established using the parameters of 
peripheral and focal necrosis, peripheral ballooning cells, inflammatory infiltration, and 
peripheral fibrosis. Ballooning degeneration is an often-used term in liver morphology, 
which indicates hepatocyte degeneration that is associated with swelling, rounding, and 
enlargement of hepatocytes, along with characteristically reticulated cytoplasm [19]. 
Application of this term has been observed in acute viral hepatitis, alcoholic and non-
alcoholic steatohepatitis, autoimmune hepatitis, Wilson’s disease, neonatal giant cell 
hepatitis, toxic liver damage and ischemia/reperfusion injury of liver allografts cases. 
Shape and size of hepatocytes may be affected by the amount of intracellular organelles 
and other cytoplasmic components, cytoskeletal architecture, fluid retention, or a 
combination of these factors [19]. The following histopathological scoring system was 
utilized: 0 - No Change; 1 - Very slight change; 2 - Slight change; 3 - Moderate change; 4 
– Severe change. 
Sirius Red (Direct Red 80) is a polyazo dye, which is used in a diversity of clinical cases 
with the primary objective of observing extent of fibrosis in the event of inflammation 
caused by developing cancer, vascular, or metabolic pathologies. Using bright field 
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microscopy, nuclei and cytoplasm of cells could be seen in yellow color, while collagen 
fibers gain varying shades of red color. For Sirius Red staining, quantitative analysis was 
performed using ImageJ (https://imagej.nih.gov/ij/) at x100 magnification in four fields of 
liver tissue, which were randomly selected to calculate percent of positively stained area. 
Immunohistochemistry 
For CD68 antibody staining of liver tissue, paraffin-embedded liver sections (5 μm thick) 
were stained with primary antibodies using Dako Antibody Dilution solution (Dako, 
Carpinteria, CA). The primary antibody used in this experiment was rat anti-mouse CD68 
(MCA1957GA; Bio-Rad, Raleigh, NC; 1:50, 1 hour, room temperature). ABC method 
was performed by using VECTASTAIN Elite ABC HRP Peroxidase Rat IgG Kit (PK-
6104; Vector Laboratories, Burlingame, CA). Dako Liquid DAB+ Substrate chromogen 
System (Dako, Carpinteria, CA) was employed for visualization. Slides were 
counterstained with filtered Mayer’s hematoxylin (Sigma) for 60 seconds. Quantitative 
analysis was performed manually by counting CD68-positive cells at x200 magnification 
in four fields of liver tissue, which were randomly selected to calculate percent of 
positively stained area. 
KIM-1 staining of kidney tissue specifically marks Kidney Injury Molecule-1 (KIM-1), 
type 1 transmembrane protein, expression of which is markedly upregulated in proximal 
kidney tubule in the event of acute kidney injury [20]. For KIM-1 antibody staining of 
kidney tissue, paraffin-embedded kidney sections (5 μm thick) were stained with primary 
antibodies using Dako Antibody Dilution solution (Dako, Carpinteria, CA). The primary 
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antibody used in this experiment was: goat anti-mouse KIM-1 (AF1817; R&D Systems, 
Minneapolis, MN; 1:50, 1 hour, room temperature). Rabbit anti-goat IgG Antibody, HRP 
conjugate (AP106P; EMD Millipore, Billerica, MA, 1:2000, 1 hour, room temperature) 
was used secondarily. Dako Liquid DAB+ Substrate chromogen System (Dako, 
Carpinteria, CA) was employed for visualization. Slides were counterstained with filtered 
Mayer’s hematoxylin (Sigma) for 60 seconds. Quantitative analysis was performed 
manually by counting number of KIM-1 positive proximal tubules and calculating ratio of 
CD68-positive cells at x200 magnification in four fields of kidney tissue, which were 
randomly selected to calculate percentage of positively stained area. 
Serum clinical chemistry 
Hepatocellular damage releases transaminase enzymes, specifically alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), into the bloodstream. ALT 
is primarily contained in the liver; however, AST is also found in erythrocytes and skeletal 
muscle [21]. Therefore, serum ALT elevations are, generally speaking, more specific for 
hepatic injury [21].  
Serum collection was performed at the time of necropsies via Z-gel tubes (Sarstedt, 
Nümbrecht, Germany). Serum alanine aminotransferase (ALT) and serum aspartate 
aminotransferase (AST) levels were measured with a commercially-available kit (Sigma 
Aldrich, St. Louis, MO) according to manufacturer’s instructions.  
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RNA isolation and quantitative reverse transcription PCR 
Total RNA was extracted from liver using the RNeasy Mini kit (Qiagen, Valencia, CA). 
RNA concentrations were measured with NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE) and quality was verified using the Bio-
Analyzer (Agilent Technologies, Santa Clara, CA).  
Total RNA was reverse transcribed using random primers and the high capacity cDNA 
archive kit (Applied Biosystems, Foster City, CA). Reactions were performed in a 96-well 
assay format using a QuantStudio™ 7 Flex Real-Time PCR System (Life Technologies). 
The mRNA level of the housekeeping gene, TATA-Box binding protein (Tbp; 
Hs00427620_m1), was evaluated in tandem with each experimental run. The relative level 
of each transcript was determined using the 2-ΔΔCt method [22].  
Primers, which were used for detection of gene expression of pro-inflammatory markers, 
CYP450 superfamily enzymes, and kidney injury markers, are shown in Table 1.  
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Table 1. List of primers used in RT-qPCR for detection of gene expression of pro-
inflammatory markers, CYP450 enzymes, and kidney injury markers 
 
Gene Name Gene Symbol Assay ID Organ 
Tumor necrosis factor alpha Tnf Mm00443258_m1  
 
 
 
 
Liver 
TIMP metallopeptidase inhibitor 1 Timp1 Hs01092512_g1 
Interleukin 1 beta Il1 Hs01555410_m1 
Transforming growth factor beta 1 Tgfb1 Hs00998133_m1 
C-C motif chemokine receptor 5 Ccr5 Hs99999149_s1 
NAD(P)H quinone dehydrogenase 1 Nqo1 Hs01045993_g1 
Heme oxygenase 1 Hmox1 Hs01110250_m1 
Epithelial cell adhesion molecule Epcam Hs00901885_m1 
CD68 molecule Cd68 Hs02836816_g1 
Alpha fetoprotein Afp Hs01040598_m1 
Keratin 7 Krt7 Hs00559840_m1 
Cytochrome P450 1 A 2 Cyp1a2 Hs00167927_m1  
 
Liver, 
kidney 
Cytochrome P450 2 B 10 Cyp2b10 Mm01972453_s1 
Cytochrome P450 2 E 1 Cyp2e1 Hs00559367_m1 
Cytochrome P450 3 A 11 Cyp3a11 Mm00731567_m1 
Cytochrome P450 4 A 10 Cyp4a10 Mm02601690_gH 
Hepatitis A virus cellular receptor 1 Kim1 Hs00930379_g1 Kidney 
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Western blot analysis of CYP2E1 
Liver tissue lysates were prepared by homogenization in lysis buffer (50mM Tris-HCl, pH 
7.4; 1% NP-40; 1.0% sodium dodecyl sulfate; 150mM NaCl; 1mM EDTA; 1mM PMSF; 
and 1.5mM dithiothreitol), sonication, and incubation at 4°C for 30 min, followed by 
centrifugation at 10,000 g at 4°C for 10 min. Protein concentrations in the extracts were 
quantified by Bradford assay (Bio-Rad, Hercules, CA) using Synergy™ H4 hybrid multi-
mode microplate reader (BioTek, Winooski, VT).  Extracts containing equal quantities of 
proteins were separated by SDS-PAGE on 15% polyacrylamide gels and transferred to 
PVDF membranes. Membranes were probed with primary antibody against cytochrome 
P450 2E1 protein (ab28146; Abcam, Cambridge, MA; 1:1000). Blots were scanned and 
analyzed using the Odyssey CLx Infrared Imaging System (LI-COR Biosciences). Amido 
Black staining of proteins on transferred membrane blots was performed. 
Statistical analysis 
Statistical significance was determined using GraphPad Prism5 v5.0 (San Diego, CA). 
Quantitative values are expressed as mean±SD unless otherwise noted. Statistical 
significance was evaluated using one-way ANOVA within each time point followed by 
the Tukey's post hoc test. Statistical significance is indicated at any level below p < 0.05. 
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CHAPTER IV 
RESULTS 
Results of dose-finding study (PFD_DS) 
PFD_DS is a 4-week dose-finding study, in which 40 male B6C3F1/J mice were treated 
with CCl4 (0.2 ml/kg intraperitoneal injections twice a week) while on diet with varying 
doses of pirfenidone (0 mg/kg, 100 mg/kg, 300 mg/kg, 600 mg/kg). Experimental design 
for this study is described in Figure 2. 
Body and organ weight 
Body weight was measured regularly to track the general state of health of animals. 
Animals in every group were gaining body weight over the duration of the study; mice in 
CCl4+300 mg/kg pirfenidone diet and CCl4+600 mg/kg pirfenidone diet groups have 
shown to gain weight more slowly, as compared to CCl4+CD and CCl4+100 mg/kg 
pirfenidone diet group (Figure 5). A noticeable 6-8% drop in body weight was observed 
among the groups after several initial intraperitoneal injections of either olive oil or carbon 
tetrachloride. This negative change may be explained by overall stress of animals and 
change in eating habits after the initiation of intraperitoneal injections containing irritative 
compounds. This decrease in body weight did not affect the course of the study. After all 
mice adjusted to the procedure and new diet, their weight started to increase on day 6 of 
injections. Subsequently, several minor fluctuations in body weight among all treatment 
groups were observed on days 10 and 26, which did not affect the course of the study. 
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Figure 5. Body weight change among treatment groups (A) and further stratification 
of groups by different diet forms (B) in dose-finding study (PFD_DS) 
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Relative liver weight was significantly increased in CCl4+300 mg/kg pirfenidone diet 
compared to CCl4+CD group. Relative liver weight was also increased in CCl4+600 mg/kg 
pirfenidone diet group compared to both CCl4+CD and CCl4+100 mg/kg pirfenidone diet 
groups (Figure 6). There was no significant difference in relative kidney weight, relative 
spleen weight, and relative lung weight among the treatment groups (Figure 6). 
 
 
 
 
 
 
 
 
 
Figure 6. Relative liver (A), kidney (B), spleen (C), and lung (D) weights in dose-
finding study (PFD_DS). All data are presented as mean ± SD. ap < 0.05, compared to 
CCl4+CD group; 
bp < 0.05, compared to CCl4+PFD(100mg/kg) group; NS describes 
no significant difference among groups 
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Serum clinical chemistry 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serum levels were 
significantly decreased and AST to ALT ratio was significantly higher in CCl4+300 mg/kg 
pirfenidone diet and CCl4+600 mg/kg pirfenidone diet groups, compared to CCl4+CD 
group, with no significant difference between diets in pellet and powder forms (Figure 7).  
 
Figure 7. Serum ALT and AST in dose-finding study (PFD_DS). All data are 
presented as mean ± SD. 
Top row: ap < 0.05, compared to CCl4+CD group; 
bp < 0.05, compared to CCl4+PFD 
(100mg/kg) group; cp < 0.05, compared to CCl4+PFD (300mg/kg) group; 
dp < 0.05, 
compared to CCl4+PFD (600mg/kg). Bottom row: 
ap < 0.05, compared to CCl4+CD 
(powder form) group; bp < 0.05, compared to CCl4+CD (pellet form) group; 
cp < 0.05, 
compared to CCl4+PFD (100mg/kg, powder form) group; 
dp < 0.05, compared to 
CCl4+PFD (100mg/kg, pellet form) 
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Histopathological evaluation of liver tissue 
Hematoxylin and eosin staining of liver tissue slides was performed. Hepatocellular 
necrosis (arrow), cellular infiltration (inflammation), and ballooning cell accumulation 
(hydropic degeneration, arrowhead) were observed in the centrilobular region of liver 
among all treatment groups, with a visible decrease in intensity of all described parameters 
correlating with an increase in dosage of pirfenidone (representative image of H&E 
staining of mouse liver from CCl4+CD treatment group is shown in Figure 8). 
 
Figure 8. Representative histology of CCl4/CD-treated, H&E-stained mouse liver in 
dose-finding study (PFD_DS). Hepatocellular necrosis is shown by arrow and 
ballooning cell accumulation (hydropic degeneration) is shown by arrowhead. 
Original magnification is x200 
 
X200 
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Total histopathology score was calculated, using the parameters of necrosis, ballooning, 
inflammation, and fibrosis (Figure 9). Both CCl4+300 mg/kg pirfenidone diet and 
CCl4+600 mg/kg pirfenidone diet groups have shown significantly lower histopathology 
score values in comparison to CCl4+CD group. 
 
 
 
 
 
Figure 9. Total histopathology score (A) in dose-finding study (PFD_DS). Four 
parameters were used to calculate total score (B). 
All data are presented as mean ± SD. ap < 0.05, compared to CCl4+CD group; 
bp 
< 0.05, compared to CCl4+PFD (100mg/kg) group; NS describes no significant 
difference among groups 
NS NS 
NS A B 
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To evaluate the intensity of fibrosis in liver, a Sirius Red staining of liver tissue slides has 
been performed, and average Sirius Red-positive area of four representative images of 
each liver sample was calculated using image processing program ImageJ (Figure 10). 
There was a significant decrease in Sirius Red-positive area percentage in CCl4+300 
mg/kg pirfenidone diet group compared to CCl4+CD group, and similarly significant 
decrease compared to both CCl4+CD and CCl4+100 mg/kg pirfenidone diet groups. There 
was no significant difference in Sirius Red-positive area percentage between CCl4+300 
mg/kg pirfenidone diet and CCl4+600 mg/kg pirfenidone diet groups.  
 
 
 
 
 
 
 
 
 
 
A 
Figure 10. Representative images of Sirius Red staining of liver (A, B) and Sirius 
Red-positive area quantification (C) in dose-finding study (PFD_DS). All data are 
presented as mean ± SD. ap < 0.05, compared to CCl4+CD group; 
bp < 0.05, compared 
to CCl4+PFD (100mg/kg) group. Original magnification is x100 
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Immunohistochemistry 
Immunohistochemical staining by anti-CD68 antibody was performed, and the manual 
quantification of CD68-positive cells of four representative images of each liver sample 
showed no significant difference among treatment groups (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Representative images of CD68 staining of liver (A, B) and CD68-positive 
cells count (C) in dose-finding study (PFD_DS). All data are presented as mean ± SD. 
NS describes no significant difference among groups. Original magnification is x200 
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KIM-1 staining of kidney tissue was performed to help identify the extent of possible 
kidney injury. Manual quantification of KIM-1 positive tubules was conducted, and 
subsequent analysis showed no significant difference in number of KIM-1 positive tubules 
among treatment groups (Figure 12, Panels A, B, C). There was no significant difference 
in gene expression of hepatitis A virus cellular receptor 1 (Kim1) among groups (Figure 
12, Panel D).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Representative images of KIM-1 staining of kidney (A, B), KIM-1-positive 
tubules count (C), and kidney Kim1 mRNA expression (D) in dose-finding study 
(PFD_DS). All data are presented as mean ± SD. NS describes no significant difference 
among groups. Original magnification is x200 
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Gene expression of profibrogenic proteins in liver and gene expression of CYP450 
family proteins in kidney 
To assess expression of certain genes in liver and kidney, RNA isolation with subsequent 
quantitative reverse transcription polymerase chain reaction was performed. 
In liver, there was no significant inter-group difference in gene expression of assessed 
profibrogenic protein markers, specifically Timp1, Nqo1, Epcam, Cd68, Afp, and Krt7. 
(data not shown). 
In both liver and kidney, there was no significant inter-group difference in gene expression 
of proteins of cytochrome P450 enzyme family, specifically Cyp1a2, Cyp2b10, Cyp2e1, 
Cyp3a11, and Cyp4a10. (data not shown). 
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Western blot analysis of CYP2E1 
To assess CYP2E1 protein levels in liver, Western blot technique was conducted, and its 
results showed significant increase in CYP2E1 protein levels in livers of mice in CCl4+300 
mg/kg pirfenidone diet treatment group, as compared to CCl4+CD group (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. CYP2E1 protein levels in liver in dose-finding study (PFD_DS). Data is 
presented as mean ± SD. ap < 0.05, compared to CCl4+CD group (A). Detected 
CYP2E1 and -actin protein bands across treatment groups are shown on (B). 
Representative image of Amido Black stain of proteins on membrane is shown on (C). 
A 
C 
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Results of sub-chronic study (PFD_AS) 
PFD_AS is a 14-week subchronic study, in which 20 male B6C3F1/J mice were treated 
with CCl4 (0.2 ml/kg intraperitoneal injections twice a week), while being on 300 mg/kg 
pirfenidone diet. Experimental design for this study is presented in Figure 3. 
Body and organ weight 
Body weight was assessed regularly to track the general state of health of animals. Animals 
in every group were gaining body weight over the duration of the study; mice in CD+CCl4 
and PFD+CCl4 groups were gaining weight slower as compared to CD+OO and PFD+OO 
groups (Figure 14).  
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Figure 14. Body weight change in sub-chronic study (PFD_AS) among treatment 
groups 
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A noticeable 10% drop in body weight was observed in PFD+CCl4 group, which may be 
explained by change in eating habits after the initiating intraperitoneal injections and a 
new diet; after adjustment to procedure and change in diet, their weight started to increase 
after day 4 of injections. In addition, minor fluctuations in body weight among all 
treatment groups were observed throughout the study. 
Liver-to-body weight ratio was significantly increased in OO+PFD, CCl4+CD, and 
CCl4+PFD groups, compared to CCl4+CD group (Figure 15). 
There was no significant difference in kidney-to-body weight ratio among the treatment 
groups (Figure 15). 
Spleen-to-body weight ratio was significantly higher in CCl4+CD and CCl4+PFD groups 
in comparison to both OO+CD and OO+PFD groups (Figure 15). 
 
 
Figure 15. Organ-to-body weight ratios in sub-chronic study (PFD_AS). All data are 
presented as mean ± SD. ap < 0.05, compared to OO+CD group; bp < 0.05, compared 
to OO+PFD group; NS describes no significant difference among groups 
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Serum clinical chemistry 
Alanine aminotransferase (ALT) serum level was significantly increased in CCl4+PFD 
treatment group (Figure 16).  
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Figure 16. Serum ALT in sub-chronic study (PFD_AS). All data are presented as mean 
± SD. ap < 0.05, compared to OO+CD group; bp < 0.05, compared to OO+PFD group 
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Histopathological evaluation of liver tissue 
Hematoxylin and eosin staining of liver tissue slides was performed. In the centrilobular 
region, cellular infiltration (inflammation) and fibrosis (arrow) were observed in the 
CCl4+CD and CCl4+PFD groups. Hepatocellular degeneration, necrosis, cellular 
infiltration (inflammation), increase in mitotic figures of hepatocytes, and fibrosis were 
equally observed in CCl4+CD and CCl4+PFD-treated mice with no significant difference 
between treatment groups. Total histopathology score was calculated, using established 
parameters of necrosis, ballooning, inflammation, and fibrosis (Figure 17). Both 
CCl4+CD and CCl4+PFD treatment groups have shown similar histopathology score 
values with no significant difference between them. Representative image of H&E 
staining of mouse liver from CCl4+CD treatment group is shown in Figure 18. 
 
 
Figure 17. Total histopathology score in sub-chronic study (PFD_AS). All data are 
presented as mean ± SD. NS describes no significant difference among groups 
 NS 
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Sirius Red staining of liver tissue slides showed a significant reduction in Sirius Red-
positive area percentage in CCl4+PFD group compared to CCl4+CD group (Figure 19). 
Figure 18. Representative images of CCl4-treated, H&E stained mouse liver with 
administration of different diets in sub-chronic study (PFD_AS). Cellular infiltration 
and fibrosis are shown by arrow. Original magnification is x200 
X200 
X200 
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Immunohistochemistry 
There was no significant difference in number of KIM-1 positive tubules and in Kim1 gene 
expression among treatment groups (Figure 20). 
Figure 19. Representative images of Sirius Red staining of liver (A) and Sirius Red-
positive area quantification (B) in sub-chronic study (PFD_AS). Data is presented as 
mean ± SD. ap < 0.05, compared to OO+CD group; bp < 0.05, compared to OO+PFD 
group; cp < 0.05, compared to CCl4+CD group. Original magnification is x100 
A 
B 
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Figure 20. Representative images of KIM-1 staining of kidney (A), KIM-1-positive 
tubules count (B), and kidney Kim1 mRNA expression (C) in sub-chronic study 
(PFD_AS). Scatter plot for % of KIM-1 positive tubules is shown (line, median; 
whiskers, standard deviation). KIM-1 mRNA expression data is presented as mean ± 
SD. NS - no significant difference. Original magnification is x200 
 
O
O
/C
D
O
O
/P
F
D
C
C
L
4
/C
D
C
C
L
4
/P
F
D
-2
0
2
4
6
8 N S
%
 o
f 
K
im
-1
 p
o
s
it
iv
e
 t
u
b
u
le
s
 
X200 
X200 
X200 
X200 
A 
B C 
K
im
1 
m
R
N
A
 e
xp
re
ss
io
n
 
(N
o
rm
al
iz
ed
 t
o 
O
O
+C
D
 g
ro
u
p
) 
 47 
 
 
Gene expression of profibrogenic proteins in liver 
To measure expression of certain genes in liver, RNA isolation with subsequent 
quantitative reverse transcription polymerase chain reaction was conducted. 
In both treatment groups receiving CCl4, there was a significant increase in gene 
expression of several profibrogenic and proinflammatory markers, specifically of genes 
Tnf, Ccr5, Nqo1, and Hmox1 (Figure 21). 
Gene expression of I11 and Tgfb1 was significantly decreased in CCl4+CD group (Figure 
21). 
There was no significant inter-group difference in gene expression of Timp1 (Figure 21). 
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Figure 21. Tnf(A), Timp1 (B), Il1(C), Tgfb1 (D), Ccr5 (E), Nqo1 (F), and Hmox1 (G) 
mRNA expression in liver in sub-chronic study (PFD_AS). All data are presented as 
mean ± SD. ap < 0.05, compared to OO+CD group; bp < 0.05, compared to OO+PFD 
group; cp < 0.05, compared to CCl4+CD group 
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Results of anti-cancer study (PFD_MS) 
PFD_MS is a 24-week anti-cancer study, in which 112 male B6C3F1/J mice were exposed 
to single injection of either N-nitrosodiethylamine (DEN) or phosphate-buffered saline, 
followed with 14-week treatment by olive oil or CCl4 in combination with pirfenidone 
(300 mg/kg) or control diet. Experimental design for this study is shown in Figure 4. 
Body and organ weight 
Animals in every group were gaining body weight over the duration of the study; mice in 
DEN+CD/CCl4 and DEN+PFD/CCl4 groups were experiencing delayed and more gradual 
increase in body weight in comparison to PBS+PFD/OO and DEN+PFD/OO groups 
(Figure 22).  
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Figure 22. Body weight change in anti-cancer study (PFD_MS) among treatment 
groups 
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Liver-to-body weight ratio was significantly higher in DEN+CCl4/CD and 
DEN+CCl4/PFD groups, compared to PBS+OO/PFD and DEN+OO/PFD groups (Figure 
23). 
There was no significant difference in kidney-to-body weight ratio among the treatment 
groups (Figure 23). 
Similarly to liver-to-body weight ratio, spleen-to-body weight ratio was significantly 
increased in DEN+CCl4/CD and DEN+CCl4/PFD groups in comparison to PBS+OO/PFD 
and DEN+OO/PFD groups (Figure 23). 
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Figure 23. Organ-to-body weight ratios in anti-cancer study (PFD_MS). All data are 
presented as mean ± SD. ap < 0.05, compared to PBS+OO/PFD group; bp < 0.05, 
compared to DEN+OO/PFD group. NS describes no significant difference among 
groups 
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Assessment of tumor incidence, multiplicity, and size 
Quantification of visible liver tissue tumors and consequent comparison of tumor amount 
per liver between groups did not show significant difference between pirfenidone diet and 
control diet groups (Figure 24). 
 
 
 
 
 
 
 
Figure 24. Tumor incidence, multiplicity and size in anti-cancer study (PFD_MS). All 
data are presented as mean ± SD. ap < 0.05, compared to PBS+OO/PFD group; bp < 
0.05, compared to DEN+OO/PFD group. NS - no significant difference 
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Histopathological evaluation of liver tissue 
Hematoxylin and eosin staining of liver tissue slides was performed. In the 
DEN+CCl4/CD, the number of tumors and foci on the section was about 1 to 10. The size 
of tumors in the DEN+CCl4/CD was larger than that in the DEN+OO/PFD. All tumors 
were hepatocellular adenoma (benign), and all foci were of basophilic type. 
Representative image of H&E staining of mouse liver from DEN+CCl4/CD treatment 
group is shown in Figure 25. In the DEN+OO/PFD group, the number of tumors and foci 
on the section was about 1 or 2, and all tumors were hepatocellular adenomas (benign). 
All foci were of basophilic type. Representative image of H&E staining of mouse liver 
from DEN+OO/PFD treatment group is shown in Figure 26. 
 
 
 
 
 
 
 
 
 
 
Figure 25. Representative images of DEN/CCl4+CD-treated, H&E-stained mouse 
liver in anti-cancer study (PFD_MS). Representation of hepatocellular adenomas in 
liver tissue is shown on (A) (original magnification x4). Closer view of hepatocellular 
adenoma is shown on (B) (original magnification x100) 
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Figure 26. Representative images of DEN/OO+PFD-treated, H&E-stained mouse liver 
in anti-cancer study (PFD_MS). Representation of hepatocellular adenomas in liver 
tissue is shown on (A) (original magnification x4). Closer views of hepatocellular 
adenoma (B) and focus of cellular alteration (C) are represented with original 
magnification x100 
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In DEN+CCl4/PFD group, the number, size, and histopathological features of induced-
tumor were of the same level as in DEN+CCl4/CD group. Representative image of H&E 
staining of mouse liver from DEN+CCl4/PFD treatment group is shown in Figure 27. 
 
 
 
 
 
Total histopathology score was established, using the same parameters as in previous two 
studies. Values were similar to sub-chronic study, and there was no significant difference 
between DEN+CCl4/CD and DEN+CCl4/PFD treatment groups (data not shown). 
 
 
Figure 27. Representative images of DEN/CCl4+PFD-treated, H&E-stained mouse 
liver in anti-cancer study (PFD_MS). Representation of hepatocellular adenomas in 
liver tissue is shown on (A) (original magnification x4). Closer view of hepatocellular 
adenoma is shown on (B) (original magnification x100) 
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CHAPTER V 
SUMMARY, DISCUSSION, AND FUTURE DIRECTIONS 
Summary 
In pirfenidone dose-finding study, the results of Sirius Red staining showed significant 
reduction of collagen deposition in liver with pirfenidone administration in the event of 
sub-acute CCl4-induced cytotoxic fibrosis. Decrease in the amount of “ballooning” 
hepatocytes was observed at 300 and 600 mg/kg doses. Decrease in serum transaminase 
levels supported the theory of proposed beneficial effects of pirfenidone in reducing 
hepatocyte damage. As confirmed by results of KIM-1 staining, there was no difference 
in the extent of kidney injury with addition of pirfenidone compound in diet. Based on 
these results, it has been concluded that pirfenidone dose of 300 mg/kg/day is the lowest 
effective dose that shows significant reduction in the intensity of liver fibrosis, and does 
not cause kidney injury in in sub-acute liver fibrosis model. 
In pirfenidone sub-chronic study, a previously established dose of 300 mg/kg has been 
used to examine effects of pirfenidone in 14-week treatment by CCl4. 14-week pirfenidone 
treatment also decreased collagen deposition in liver. Pirfenidone administration had little 
effect on the markers of inflammation and liver injury. KIM-1 staining [20] showed no 
difference in severity of kidney injury between control diet and pirfenidone diet, which 
was consistent with results of dose-finding study. 
In pirfenidone anti-cancer study, it was expected that the incidence of liver tumors induced 
by consecutive administration of DEN and CCl4 will be 100%, consistent with original 
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model [18]. The results of tumor quantification confirmed this expectation. Addition of 
pirfenidone treatment did not affect incidence, multiplicity, and size of liver tumors. 
Discussion 
Liver fibrosis and its complications in form of liver cirrhosis and hepatocellular carcinoma 
constitute a major portion of morbidity and mortality in human population worldwide. 
Although multiple experimental preventative and therapeutic approaches were proposed 
to target progression of liver fibrosis and consequential carcinogenesis [1, 6], few to this 
date were found to bear a desirable effect that would result in reduction in intensity of 
liver fibrosis, and none decreased the incidence of post-fibrotic tumorigenesis in livers of 
experimental animals. In this context, a better understanding of anti-fibrotic effects of 
pirfenidone, established treatment approach for pulmonary fibrosis, was necessary to 
possibly enhance management options for similar condition in liver. Pirfenidone 
demonstrated anti-fibrotic effects in liver in both sub-acute and sub-chronic studies; 
however, anti-inflammatory properties were observed only in sub-acute study. In addition, 
as there are established mechanisms of fibrosis-associated promotion of liver 
carcinogenesis [5, 18], it was important to investigate the role of pirfenidone in liver tumor 
development. Unfortunately, pirfenidone has no effect on development of liver tumors in 
anti-cancer study. 
Observations of reduction in liver fibrosis intensity confirm the first hypothesis stating 
that pirfenidone suppresses fibrogenesis in liver, which correlates well with findings of 
other studies [23, 24]. 
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While a decrease in serum biomarkers of liver injury was observed is sub-acute study, the 
findings did not correspond to results of sub-chronic study, in which no such reduction 
was observed. This nonconformity may be explained by different period of exposure to 
hepatotoxic compound and decrease in efficacy of pirfenidone in such circumstances. It is 
worth noting that 3-week pirfenidone treatment decreased AST 3-fold and ALT 2-fold 
after 8 weeks of intoxication by CCl4 in previously established rat model of experimental 
liver fibrosis [23], although the compound was administered by gavage in that case. 
Findings of the current study do not demonstrate an existing effect of pirfenidone on 
accumulation of hepatic macrophages, which normally constitute largest non-
parenchymal cell population in the liver, being involved in promotion of fibrosis through 
recruitment of pro-inflammatory immune cells, secretion of pro-inflammatory cytokines 
and chemokines, and resolution of fibrotic process by secreting metalloproteinases in late 
stages [25, 26]. Currently acquired data does not correspond to evidence of suppression of 
macrophage accumulation by pirfenidone in rat model of renal fibrosis [27]. Described 
differences in effects of pirfenidone on macrophage infiltration might base on evaluation 
of different target organs, distinctive animal species, as well as disparate treatment 
duration. 
Gene expression of growth factors and proinflammatory cytokines (Tgfb1, Tnf, Il1, Il6), 
whose regulation and tissue levels were previously downregulated in pulmonary fibrosis 
[12, 28, 29] and liver fibrosis models [23, 24], was not affected by both sub-acute and sub-
chronic exposure to pirfenidone (with the exception of Tgfb1 gene expression, which was 
increased in sub-chronic study). The discrepancies between the findings of studies may be 
 58 
 
 
caused by such differences, duration of pirfenidone treatment, duration of toxicant 
exposure, species and strains of animals used, and age of animals at the start of experiment. 
While establishing the lowest effective dose of pirfenidone in sub-acute liver fibrosis 
model, special attention has been directed towards possible detrimental effects of the 
compound on kidney, and the conclusion has been made that pirfenidone does not affect 
the kidney even in the highest evaluated dose. These findings may contribute to future 
evaluations of safety of pirfenidone and decisions of the compound use in patients with 
pre-existing kidney diseases. 
Although CYP2E1 enzyme is only partially involved in metabolism of pirfenidone (which 
is mainly metabolized by CYP1A2 enzyme), it is worth noting that change in pirfenidone 
dosage did not cause any shifts in CYP2E1 expression, which correlates with the existing 
data [12] and does not reflect any interactions between CCl4 and pirfenidone that might 
affect efficacy of the latter. The absence of anti-inflammatory effects of the compound in 
sub-chronic cytotoxic study may have resulted from decreased efficacy of pirfenidone in 
presence of potent cytotoxic chemical. A possibility of interactions in CYP450 
metabolism of pirfenidone and CCl4 should be considered in establishing cause of 
discrepancies between current and previous studies, in which pirfenidone showed potent 
anti-inflammatory properties [23, 30].  
Finally, cytotoxic liver fibrosis model might not be the best appropriate tool for evaluation 
of pirfenidone effects, and anti-fibrotic potential of the compound may be better evaluated 
in studies utilizing milder and more gradual fibrogenic treatment, such as dietary exposure 
 59 
 
 
to DDC (3,5-diethoxycarbonyl-1,4-dihydrocollidine), or sub-chronic treatment with 
ethanol by oral gavage or implanted intragastric tubes. 
The second hypothesis, which addressed possible role of pirfenidone in reduction of 
incidence, size, and multiplicity, was refuted.  
It is worth noting that the findings regarding tumor incidence with usage of DEN and CCl4 
– induced liver cancer model were consistent with the original protocol [18]. Model 
chosen to evaluate pirfenidone in suppression of liver tumorigenesis might not fully reflect 
anti-fibrotic and, subsequently, anti-cancer properties of compound due to severity of 
carcinogenic effect of combined DEN and CCl4 treatment. Assessment of pirfenidone anti-
cancer efficacy may be further conducted with possibly more beneficial outcomes using 
different liver tumorigenesis model with lower incidence of tumors, such as with aflatoxin 
B1 or thioacetamide treatment [17]. 
Efficacy of pirfenidone might be more pronounced in the event of oral gavage treatment 
instead of continuous voluntary exposure to drug-containing diet [23]. Anti-fibrotic 
properties of pirfenidone might diminish over time in case of diet location in animal cage 
for several days at the time at least. 
Previously conducted studies demonstrated important role of pirfenidone in inhibition of 
pancreatic cancer desmoplasia by regulating stellate cells in vitro [31] and enhancement 
of the efficacy of combined radiation and sunitinib therapy in Lewis lung carcinoma [32]. 
Current study did not exhibit positive effects of pirfenidone on tumorigenesis in liver, 
which may be explained by specific mechanism of action of the compound and differences 
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in pathogenesis of these diseases. Mouse strain variabilities and possible effects of CCl4 
on pirfenidone metabolism by CYP450 system should also be considered. 
Future directions 
Liver fibrosis is a major health problem in the United States and developing countries. 
Discovery of effective medication for prevention and treatment of liver fibrosis 
development will reduce incidence of the disease, broaden therapeutic choices, and 
improve quality of life of affected individuals.  
It could be stated that pirfenidone compound has promising beneficial effects, which may 
find application in treatment of human hepatic fibrosis caused by a diversity of causes, 
and results of this study may be helpful in determining directions and strategies for future 
pre-clinical studies and clinical trials of pirfenidone compound. 
Additionally, other experimental treatments may be applied in similar setting of cytotoxic 
liver fibrosis caused by CCl4, both as individual approaches and in combination with 
pirfenidone administration.  
Considering absence of anti-cancer effect of pirfenidone in this study, it may be worth to 
examine application of other experimental approaches for prevention of hepatocellular 
carcinoma in existing DEN and CCl4 - induced mouse model of fibrosis and inflammation-
associated hepatocellular carcinoma, such as S-Adenosylmethionine [33]. 
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